Results 11 to 20 of about 83,328 (323)

Outcomes of Nivolumab‐Plus‐Ipilimumab in Metastatic Renal Cell Carcinoma: Second Interim Analysis of the J‐ ENCORE Study [PDF]

International Journal of Urology, EarlyView.
ABSTRACT Objectives J‐ENCORE is a multicenter prospective observational study in Japan involving advanced or metastatic renal cell carcinoma patients receiving nivolumab‐plus‐ipilimumab (NIVO+IPI) as first‐line treatment. The minimum 1‐year observation revealed the efficacy and safety of NIVO+IPI comparable to those in CheckMate 214, and evaluated ...
Tomokazu Sazuka, Katsunori Tatsugami, Suguru Shirotake, Shuzo Hamamoto, Masahiro Nozawa, Kazuyuki Numakura, Takashige Abe, Kojiro Ohba, Go Kimura   +8 more
openalex   +2 more sources

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma

Journal of Clinical Oncology, 2021
PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes.
J. Wolchok, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, M. Butler, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, T. Bas, C. Ritchings, J. Larkin, F. Hodi   +28 more
semanticscholar   +1 more source

The price of tumor control [PDF]

, 2013
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients.
Bergmann, Tanja, Berking, Carola, Bockmeyer, Clemens L., Dummer, Reinhard, Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Goldinger, Simone M., Grabbe, Stephan, Gutzmer, Ralf, Göppner, Daniela, Hauschild, Axel, Hein, Rüdiger, Heinzerling, Lucie M., Hundorfean, Gheorghe, Justich, Armin, Kaehler, Katharina C., Keller, Ullrich, Klein, Christina, Loquai, Carmen, Mateus, Christine, Mohr, Peter, Moos, Roger von, Paetzold, Sylvie, Robert, Caroline, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens, Vaubel, Julia, Voskens, Caroline J., Weder, Patrik, Wilhelm, Tabea   +35 more
core   +1 more source

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

Clinical Cancer Research, 2023
Purpose: In the phase III CheckMate 238 study, adjuvant nivolumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IV melanoma, with benefit ...
J. Larkin, M. Del Vecchio, M. Mandalà, H. Gogas, A. Arance, S. Dalle, C. Cowey, M. Schenker, J. Grob, V. Chiarion-Sileni, I. Márquez-Rodas, M. Butler, Anna Maria Di Giacomo, M. Middleton, J. Lutzky, L. de la Cruz-Merino, P. Arenberger, V. Atkinson, A. Hill, L. Fecher, M. Millward, P. Nathan, N. Khushalani, P. Queirolo, C. Ritchings, M. Lobo, M. Askelson, Hao Tang, S. Dolfi, P. Ascierto, J. Weber   +30 more
semanticscholar   +1 more source

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)

Clinical and Translational Science, 2023
This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro, Thomas Yau, Anthony B. El‐Khoueiry, Masatoshi Kudo, Yun Shen, Marina Tschaika, Amit Roy, Yan Feng, Ling Gao, Urvi Aras   +9 more
doaj   +1 more source

Phase I Study of Ipilimumab Combined with Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients with Brain Metastases [PDF]

, 2018
Purpose: We performed a phase I study to determine the maximum tolerable dose (MTD) and safety of ipilimumab with stereotactic radiosurgery (SRS) or whole brain radiotherapy (WBRT) in patients with brain metastases (BM) from melanoma.
Andrews MD, David W., Daskalakis, Constantine, Dicker, Adam, MD, PhD, Eldredge-Hindy, Harriet B., Evans, James J., Farrell, MD, Christopher J, Feeney, Kendra J., Garg, Shivank, Judy, MD, Kevin, Kendra, Kari L., Kim, Lyndon, Kim, MD, Hyun, Liebner, David A., Mastrangelo, Michael, Olencki, Thomas, Palmer, Joshua D., Sato, Takami, Shi, Wenyin, Werner-Wasik, Maria, Williams, Noelle L., Wuthrick, Evan J.   +20 more
core   +2 more sources

Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.

New England Journal of Medicine, 2023
BACKGROUND The efficacy and safety of treatment with cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal-cell carcinoma are unknown.
T. Choueiri, T. Powles, L. Albiges, M. Burotto, C. Szczylik, B. Żurawski, E. Y. Yanez Ruiz, M. Maruzzo, A. Suárez Zaizar, L. Fein, F. Schutz, D. Heng, Fong Wang, F. Mataveli, Yu-Lin Chang, M. A. Van Kooten Losio, C. Suarez, R. Motzer   +17 more
semanticscholar   +1 more source

Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

Frontiers in Oncology, 2014
Stage IV metastatic melanoma patients historically have a poor prognosis with 5-10% 5-year survival. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA4), is one of the first treatments to provide beneficial durable ...
Anna M. Leung, Agnes Fermin Lee, Junko eOzao-Choy, Romela Irene Ramos, Omid eHamid, Steven J. O'Day, Myung eShin-Sim, Donald L. Morton, Mark B. Faries, Peter A. Sieling, Delphine J Lee   +10 more
doaj   +1 more source

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada

BMC Cancer, 2020
Background For novel cancer treatments, effectiveness in clinical practice is not always aligned with clinical efficacy results. As such it is important to understand a treatment’s real-world effectiveness.
Wei Fang Dai, Jaclyn M. Beca, Ruth Croxford, Wanrudee Isaranawatchai, Ines B. Menjak, Teresa M. Petrella, Nicole Mittmann, Craig C. Earle, Scott Gavura, Timothy P. Hanna, Kelvin K.W. Chan   +10 more
doaj   +1 more source

Efficacy of anti-PD-1 and ipilimumab alone or in combination in acral melanoma

Journal for ImmunoTherapy of Cancer, 2022
Background Acral melanoma is a rare melanoma subtype with poor prognosis. Importantly, these patients were not identified as a specific subgroup in the landmark melanoma trials involving ipilimumab and the anti-programmed cell death protein-1 (PD-1 ...
Bart Neyns, Lisa Zimmer, Caroline Robert, Celeste Lebbe, Olivier Michielin, Omid Hamid, Anne Zaremba, Oliver Klein, Ruth Plummer, Joanna Mangana, Paolo A Ascierto, Katharina C Kähler, Georgina V Long, Ryan Sullivan, Grant A McArthur, Michael Weichenthal, Egle Ramelyte, Meghan J Mooradian, Douglas B Johnson, Alexander Shoushtari, Christian U Blank, Judith M Versluis, Prachi Bhave, Claudia Trojanello, Lu Si, Inderjit Mehmi, Tasnia Ahmed, Alexander M Menzies, Adnan Khattak, Severine Roy, Matteo S Carlino, Paul C Lorigan, Clara Allayous, Rachel Roberts-Thomson, Florentia Dimitriou, Kathleen Batty, Thierry Lesimple, Serigne N Lo, Alexandre Wicky, Richard Heywood, Lena Tran, Anna Stansfeld, Julia K Schwarze, Andrea Maurichi, Hui-Ling Yeoh, Mario Santinami, Andrew M Haydon   +46 more
doaj   +1 more source